Perimenopause vs Thyroid vs Mood: Sorting Symptom Overlap Efficiently

Introduction

Midlife symptoms frequently challenge traditional diagnostic frameworks because they often overlap across multiple physiological and psychological conditions. Patients presenting during the menopausal transition commonly report a constellation of symptoms that may be attributed to reproductive hormonal changes, endocrine disorders, psychiatric conditions, sleep disturbances, medication effects, or a combination of these factors. As a result, clinicians must navigate a complex diagnostic landscape in which symptom overlap is the rule rather than the exception.

Consider a 48 year old patient presenting with night sweats, insomnia, irritability, anxiety, palpitations, and irregular menstrual cycles. While these symptoms may strongly suggest perimenopause, they are not specific to the menopausal transition. Hyperthyroidism, particularly autoimmune thyroid disorders such as Graves disease, can produce a similar clinical picture characterized by heat intolerance, sleep disruption, mood changes, tachycardia, and menstrual irregularities. Likewise, anxiety disorders, panic disorder, excessive caffeine consumption, stimulant medications, alcohol use, and emerging sleep disorders can contribute to overlapping symptom profiles. Similarly, a 52 year old patient experiencing fatigue, weight gain, constipation, depressed mood, cognitive slowing, and reduced concentration may be entering menopause, developing hypothyroidism, experiencing major depressive disorder, suffering from obstructive sleep apnea, or experiencing iron deficiency. In many cases, more than one condition may be present simultaneously.

The clinical challenge, therefore, is not to determine whether symptoms are exclusively hormonal or psychological. Such a binary framework oversimplifies the complexity of midlife health and risks overlooking important diagnoses. Instead, clinicians should adopt a broader and more nuanced approach that considers the interaction between endocrine, reproductive, psychiatric, metabolic, and sleep related factors. The central diagnostic question is whether the patient’s symptom pattern, chronology, physical examination findings, medication history, laboratory results, and risk factors support perimenopause, thyroid dysfunction, a mood disorder, another medical condition, or a combination of overlapping processes.

Perimenopause represents a particularly important consideration because it is characterized by substantial hormonal variability rather than a consistent pattern of hormone deficiency. Fluctuations in ovarian function during the menopausal transition can produce vasomotor symptoms, sleep disturbances, mood changes, menstrual irregularities, cognitive complaints, and changes in quality of life. Importantly, these symptoms often develop gradually and vary considerably among individuals. Because hormonal levels fluctuate significantly during this period, laboratory testing is frequently of limited diagnostic value. Consequently, perimenopause remains primarily a clinical diagnosis based on age, menstrual history, symptom patterns, and exclusion of alternative explanations when indicated.

In contrast, thyroid dysfunction is generally diagnosed through biochemical assessment. Both hypothyroidism and hyperthyroidism can mimic many manifestations of perimenopause and mood disorders. Hypothyroidism commonly presents with fatigue, weight gain, constipation, depression, cold intolerance, menstrual disturbances, and cognitive slowing. Hyperthyroidism may manifest as anxiety, irritability, insomnia, heat intolerance, palpitations, tremors, and weight loss. However, thyroid related symptoms are often nonspecific and may overlap with numerous other conditions. For this reason, thyroid stimulating hormone and, when appropriate, free thyroxine measurements remain essential components of the diagnostic evaluation when thyroid disease is suspected.

Mood disorders represent another critical consideration in midlife patients. Depression and anxiety frequently emerge or worsen during the menopausal transition, influenced by hormonal fluctuations, sleep disruption, psychosocial stressors, caregiving responsibilities, chronic medical conditions, and life transitions. Importantly, a normal thyroid stimulating hormone level does not exclude a psychiatric disorder, just as a convincing menopausal history does not eliminate the possibility of depression or anxiety. Clinical assessment remains the cornerstone of diagnosis and should include evaluation of mood symptoms, anxiety features, sleep quality, cognitive concerns, psychosocial stressors, substance use, and functional impairment.

Sleep disorders further complicate the clinical picture. Menopause related sleep fragmentation, insomnia disorder, restless legs syndrome, and obstructive sleep apnea can all contribute to fatigue, mood changes, cognitive complaints, and reduced quality of life. Sleep disturbances may both mimic and exacerbate endocrine and psychiatric conditions, creating a cycle in which symptoms reinforce one another. Comprehensive assessment of sleep quality and sleep related symptoms is therefore essential when evaluating midlife patients.

A structured diagnostic approach can help clinicians differentiate among these overlapping conditions while minimizing both underdiagnosis and unnecessary testing. Effective evaluation begins with a detailed history focused on symptom onset, menstrual changes, temporal patterns, associated features, medication use, family history, and lifestyle factors. Physical examination should assess vital signs, body weight, thyroid abnormalities, cardiovascular findings, neurologic signs, and other relevant clinical indicators. Laboratory investigations should be guided by clinical suspicion rather than indiscriminate screening, with targeted testing used to confirm or exclude specific diagnoses.

Recognizing that multiple conditions often coexist is particularly important. Perimenopause does not protect against thyroid disease, depression, anemia, or sleep disorders. Likewise, identifying one diagnosis should not prematurely terminate further evaluation when symptoms remain unexplained. A patient may simultaneously experience menopausal vasomotor symptoms, mild hypothyroidism, and clinically significant anxiety, each contributing to the overall symptom burden.

Ultimately, the evaluation of midlife symptoms requires an integrated, patient centered approach that acknowledges the complex interplay between reproductive aging, endocrine function, mental health, sleep physiology, and general medical conditions. By focusing on symptom patterns, clinical context, targeted investigations, and the possibility of overlapping diagnoses, clinicians can improve diagnostic accuracy, avoid unnecessary interventions, and provide more effective, individualized care for patients navigating the menopausal transition and related health concerns.

Why the Symptoms Overlap

Perimenopause is characterized by variable ovarian hormone production rather than a smooth decline in estrogen. Symptoms may fluctuate over weeks or months. Vasomotor symptoms, night sweats, sleep fragmentation, menstrual irregularity, genitourinary symptoms, mood changes, and perceived cognitive difficulty are common clinical concerns. Patients often describe “brain fog,” word-finding difficulty, or reduced concentration. These complaints may be amplified by disrupted sleep, mood symptoms, hot flashes, work stress, caregiving responsibilities, or other medical conditions.

Thyroid hormones affect cardiac function, gastrointestinal motility, thermoregulation, lipid metabolism, neuromuscular function, and central nervous system activity. Hyperthyroidism may cause heat intolerance, sweating, tremor, tachycardia, anxiety-like symptoms, insomnia, and weight loss. Hypothyroidism may cause fatigue, cold intolerance, constipation, dry skin, menstrual change, bradycardia, weight gain, slowed cognition, and depressive symptoms.

Mood disorders can also present physically. Major depressive disorder may involve fatigue, sleep disturbance, appetite or weight change, psychomotor slowing, impaired concentration, anhedonia, guilt, and suicidal ideation. Anxiety and panic disorders may produce palpitations, sweating, tremor, dyspnea, chest discomfort, gastrointestinal symptoms, insomnia, and difficulty concentrating. In midlife patients, these symptoms may be mistaken for thyroid disease or menopause. The reverse also occurs. Endocrine and reproductive symptoms are sometimes dismissed as anxiety.

Table 1. First-Pass Symptom Pattern Recognition

Dominant pattern	More likely diagnosis	Clinical clue
Episodic heat, flushing, sweating, and night symptoms	Perimenopause	Symptoms often occur with menstrual-cycle variability in the expected age range.
Persistent heat intolerance, tremor, tachycardia, and weight loss	Hyperthyroidism	Symptoms are less “episodic” than hot flashes and often include objective adrenergic signs.
Fatigue, cold intolerance, constipation, dry skin, and bradycardia	Hypothyroidism	Symptoms are usually persistent rather than episodic.
Low mood, anhedonia, guilt, impaired function, and sleep/appetite change	Major depressive disorder	Symptoms persist across settings and are not limited to vasomotor episodes.
Episodic fear, palpitations, dyspnea, sweating, and chest tightness	Panic disorder or anxiety	Symptoms may mimic thyrotoxicosis, so thyroid testing is appropriate when clinically indicated.

Initial Clinical Assessment

A useful first visit starts with chronology. When did symptoms begin? Were they abrupt or gradual? Are they episodic, persistent, cyclic, or clearly associated with menstrual changes? Did symptoms begin after a new medication, supplement, thyroid dose change, antidepressant change, stimulant exposure, alcohol increase, major stressor, or sleep disruption?

Menstrual history should be specific. Document cycle length, skipped cycles, bleeding duration, heaviness, intermenstrual bleeding, postcoital bleeding, contraception, hysterectomy status, oophorectomy status, pregnancy possibility, and use of hormonal therapy. Perimenopause becomes more likely when typical symptoms occur with menstrual-cycle variability in the expected age range. However, abnormal uterine bleeding still requires evaluation based on age, risk factors, and bleeding pattern.

Medication and supplement review is not optional. Thyroid hormone, amiodarone, lithium, immune checkpoint inhibitors, glucocorticoids, stimulants, decongestants, antidepressants, anticholinergics, sedative-hypnotics, alcohol, cannabis, high caffeine intake, and biotin-containing supplements can all confuse the clinical picture. Biotin is especially important because it can interfere with some thyroid immunoassays and may create a misleading laboratory pattern that resembles hyperthyroidism.

The physical examination should include vital signs, weight trend, cardiac rhythm, thyroid palpation, tremor assessment, skin and hair findings, reflexes, edema, and signs of anemia or systemic illness. The examination is often normal in perimenopause and mood disorders. It is more likely to be diagnostically helpful when thyroid disease is overt, severe anemia is present, or another systemic condition is contributing.

Table 2. Menstrual and Reproductive Clues

Finding	Interpretation
Cycle variability, skipped cycles, and vasomotor symptoms after age 45	Supports a clinical diagnosis of perimenopause when the pattern is typical.
Heavy, prolonged, intermenstrual, postcoital, or postmenopausal bleeding	Requires gynecologic evaluation rather than automatic attribution to perimenopause.
Symptoms between ages 40 and 45	FSH may support evaluation when the diagnosis is uncertain.
Menopausal symptoms before age 40	Evaluate for primary ovarian insufficiency and other causes.
Hormonal contraception or high-dose progestin therapy	May obscure menstrual pattern and make FSH interpretation unreliable.
Hysterectomy without oophorectomy	Menstrual staging is less useful; symptoms and ovarian status guide assessment.

Laboratory Strategy

Laboratory testing should answer a clinical question. It should not substitute for the history.

For typical perimenopause in patients aged 45 or older, routine FSH, estradiol, AMH, antral follicle count, or ovarian volume testing is usually unnecessary. Hormone values fluctuate during the transition and may mislead clinicians and patients. FSH may be useful in selected patients aged 40 to 45 with menopausal symptoms or in patients younger than 40 when primary ovarian insufficiency is suspected. Hormonal contraception and high-dose progestin therapy can make FSH interpretation unreliable.

TSH is reasonable when symptoms or examination findings suggest possible thyroid dysfunction. This is case finding, not population screening. Symptoms that support thyroid testing include unexplained fatigue, palpitations, tremor, heat or cold intolerance, weight change, constipation, tachycardia, bradycardia, goiter, menstrual change, new atrial fibrillation, or unexplained mood and cognitive symptoms. If TSH is abnormal, free T4 should be obtained. Total or free T3 is useful when hyperthyroidism is suspected and free T4 is normal or only mildly abnormal.

Additional testing should be individualized. CBC is reasonable when fatigue, heavy bleeding, pallor, dyspnea, or restless legs are present. Ferritin or iron studies are useful when heavy bleeding, anemia, hair loss, restless legs, or unexplained fatigue is prominent. A metabolic panel, A1c, B12, pregnancy test, inflammatory markers, or sleep evaluation may be appropriate depending on the presentation.

Borderline thyroid results should often be repeated before labeling chronic disease, especially when the clinical picture is not convincing. TSH may be transiently abnormal during illness or after medication exposure. Subclinical hypothyroidism requires careful interpretation. Persistent TSH above 10 mIU/L is more likely to warrant treatment, while lower values require individualized consideration of symptoms, free T4, thyroid peroxidase antibody status, pregnancy intentions, goiter, cardiovascular risk, and patient preference. Subclinical hyperthyroidism also requires risk stratification, especially when TSH is persistently below 0.1 mIU/L or the patient has atrial fibrillation, osteoporosis risk, or advanced age.

Table 3. Initial Testing Strategy

Clinical question	Practical test strategy
Could this be thyroid dysfunction?	Start with TSH. Add free T4 if TSH is abnormal. Add T3 when hyperthyroidism is suspected and free T4 is normal or mildly abnormal.
Is this typical perimenopause after age 45?	Usually clinical. Routine FSH, estradiol, AMH, or ovarian imaging is not needed.
Could fatigue reflect anemia or iron deficiency?	CBC and ferritin or iron studies are reasonable when heavy bleeding, restless legs, hair loss, dyspnea, or pallor is present.
Could this be depression or anxiety?	Use PHQ-9 and GAD-7 to quantify severity, then confirm with clinical assessment.
Could supplements distort testing?	Ask specifically about biotin, especially hair, skin, and nail products, before thyroid testing.
Could this be another systemic condition?	Add testing selectively, such as metabolic panel, A1c, B12, pregnancy test, or sleep evaluation, based on history and examination.

Mood Screening and Safety Assessment

Validated screening instruments play an important role in the assessment and longitudinal management of patients presenting with symptoms of depression, anxiety, or overlapping endocrine and psychiatric conditions. Standardized tools provide a structured method for quantifying symptom severity, monitoring treatment response, and facilitating communication between healthcare providers. Among the most widely used instruments are the Patient Health Questionnaire-9 (PHQ-9), which assesses the severity of depressive symptoms, and the Generalized Anxiety Disorder-7 (GAD-7), which evaluates anxiety symptom burden. These tools have demonstrated strong validity and reliability across diverse clinical settings and populations. However, while they are valuable adjuncts to clinical practice, they should not be viewed as diagnostic instruments in isolation. Screening scores must always be interpreted within the broader clinical context and integrated with a comprehensive history, physical examination, and clinical judgment.

A thorough psychiatric and psychosocial assessment remains essential when evaluating patients with symptoms that may be attributable to mood disorders, anxiety disorders, endocrine dysfunction, or a combination of these conditions. The clinical interview should extend beyond symptom checklists to explore the full spectrum of emotional, behavioral, and functional impairment. Particular attention should be given to anhedonia, which is a hallmark feature of major depressive disorder and often manifests as a diminished capacity to experience pleasure or interest in previously rewarding activities. Functional impairment should also be assessed across occupational, academic, social, and family domains, as the degree of functional decline frequently provides important insight into illness severity and treatment needs.

Sleep disturbances warrant careful evaluation because they commonly occur in both psychiatric and endocrine disorders. Insomnia, fragmented sleep, early morning awakening, hypersomnia, and nonrestorative sleep may reflect depression, anxiety, thyroid dysfunction, perimenopause, obstructive sleep apnea, or other medical conditions. Similarly, clinicians should assess for the presence of panic attacks, including sudden episodes of intense fear accompanied by symptoms such as palpitations, chest discomfort, shortness of breath, dizziness, or a sense of impending doom. These symptoms may overlap with endocrine disorders such as hyperthyroidism and therefore require careful differential diagnosis.

The interview should also explore trauma related symptoms, including intrusive memories, hypervigilance, avoidance behaviors, emotional numbing, and sleep disturbances suggestive of posttraumatic stress disorder. Substance use assessment is equally important, as alcohol, recreational drugs, prescription medication misuse, and stimulant use can contribute to or exacerbate mood and anxiety symptoms. Alcohol consumption patterns should be reviewed in detail because excessive use may both mimic and worsen psychiatric disorders while also interfering with treatment effectiveness.

Eating patterns and weight changes represent another critical component of evaluation. Alterations in appetite, restrictive eating behaviors, binge eating episodes, or notable weight fluctuations may signal underlying psychiatric disorders, endocrine abnormalities, or both. Medication review is also essential because numerous pharmacologic agents can contribute to mood disturbances, anxiety symptoms, sleep disruption, or cognitive complaints. Corticosteroids, thyroid hormone preparations, stimulants, hormonal therapies, and certain cardiovascular medications are among the agents that may influence psychiatric presentation.

Before initiating antidepressant therapy, clinicians must carefully assess the risk of bipolar disorder. Failure to identify a history of hypomania or mania may lead to inappropriate treatment and potentially precipitate mood destabilization. Key features suggestive of bipolar spectrum disorders include periods of elevated mood, decreased need for sleep, increased energy, impulsive behavior, grandiosity, rapid speech, and episodes of unusually increased productivity or goal directed activity. A detailed personal and family psychiatric history can provide valuable diagnostic clues.

Safety assessment remains the highest priority throughout the evaluation process and should never be deferred in favor of diagnostic refinement. Clinicians should directly and sensitively inquire about suicidal ideation, suicidal intent, previous suicide attempts, self harm behaviors, and access to means of self injury. Direct questioning does not increase suicide risk and is essential for identifying patients who require urgent intervention. Assessment should also include evaluation for psychotic symptoms such as hallucinations, delusions, or severe thought disorganization, as well as manic symptoms that may indicate bipolar disorder or another serious psychiatric condition.

Additional safety considerations include screening for intimate partner violence, domestic abuse, neglect, and social circumstances that may place the patient at risk. Clinicians should determine whether the individual is able to perform basic activities of daily living, maintain adequate nutrition and hydration, adhere to medical treatment, and care for dependents when applicable. Patients who demonstrate significant functional impairment, severe psychiatric symptoms, or inability to care for themselves may require urgent psychiatric evaluation or a higher level of care.

Importantly, the presence of endocrine conditions does not exclude the possibility of a coexisting psychiatric disorder. Perimenopause and thyroid dysfunction are frequently associated with symptoms such as mood changes, anxiety, irritability, fatigue, cognitive difficulties, and sleep disturbance. However, these symptoms should not automatically be attributed solely to hormonal changes. Major depressive disorder, generalized anxiety disorder, panic disorder, and other psychiatric conditions can coexist with endocrine abnormalities and may require independent evaluation and treatment.

Conversely, clinicians must avoid the common pitfall of attributing all symptoms to a psychiatric diagnosis when underlying medical conditions may be contributing. Depression and anxiety should never be used to dismiss clinically significant physical symptoms such as vasomotor instability, abnormal uterine bleeding, palpitations, unexplained weight changes, thyrotoxicosis, hypothyroidism, arrhythmias, anemia, or obstructive sleep apnea. These conditions can present with symptoms that overlap substantially with psychiatric disorders and may require targeted medical investigation and management.

An integrated, patient centered approach is therefore essential. Accurate diagnosis depends on recognizing the complex interplay between endocrine, psychiatric, and medical factors while maintaining a rigorous commitment to patient safety. The combination of validated screening tools, comprehensive clinical interviewing, thoughtful differential diagnosis, and systematic safety assessment provides the foundation for effective evaluation and treatment planning in patients presenting with overlapping mood, anxiety, and endocrine related symptoms.

Management of Perimenopause-Associated Symptoms

Treatment should be matched to the dominant symptom burden. Vasomotor symptoms, sleep disruption, heavy bleeding, genitourinary symptoms, mood symptoms, and sexual symptoms require different strategies.

Systemic hormone therapy remains the most effective treatment for bothersome vasomotor symptoms in appropriately selected patients. The benefit-risk balance is generally most favorable for healthy symptomatic patients who are younger than 60 years or within 10 years of menopause onset and who do not have contraindications. Contraindications and major cautions include unexplained vaginal bleeding, breast cancer or estrogen-sensitive malignancy, active or prior venous thromboembolism, stroke, myocardial infarction, significant liver disease, and high thrombotic risk. Product labeling and specialty guidance should be consulted for patient-specific risk assessment.

Patients with a uterus require adequate endometrial protection when systemic estrogen is used. Therapy should be individualized by route, dose, formulation, risk profile, and patient preference. Transdermal estrogen may be preferred in some patients with elevated venous thromboembolism risk, migraine considerations, hypertriglyceridemia, or other factors that make avoidance of first-pass hepatic exposure desirable.

Nonhormonal therapy is appropriate when hormone therapy is contraindicated, not preferred, or insufficient. Evidence-supported options include certain SSRIs and SNRIs, gabapentin, oxybutynin, and fezolinetant. Paroxetine mesylate 7.5 mg and fezolinetant 45 mg daily are FDA-approved nonhormonal options for moderate to severe vasomotor symptoms. Venlafaxine, desvenlafaxine, escitalopram, citalopram, gabapentin, and oxybutynin are commonly used off label for selected patients. Clonidine is no longer favored because efficacy is limited and tolerability is often poor.

Genitourinary syndrome of menopause should not be overlooked. Vaginal dryness, dyspareunia, recurrent urinary symptoms, and irritation may respond to vaginal estrogen, moisturizers, lubricants, vaginal prasterone, or ospemifene, depending on patient history and contraindications. Systemic therapy is not required for many isolated genitourinary symptoms.

Table 4. Perimenopause Treatment Options and Safety

Option	Best clinical fit	Key cautions and monitoring
Systemic hormone therapy	Most effective option for bothersome vasomotor symptoms in appropriate candidates	Avoid or seek specialist input with unexplained bleeding, estrogen-sensitive cancer, active or prior VTE, stroke, MI, severe liver disease, or high thrombotic risk. Patients with a uterus need endometrial protection.
Vaginal estrogen or other local therapy	Genitourinary syndrome of menopause	Evaluate unexplained bleeding. Use individualized discussion in patients with breast cancer history, especially those receiving aromatase inhibitors.
SSRIs or SNRIs	Vasomotor symptoms with coexisting depression or anxiety, or when hormone therapy is not preferred	Screen for bipolar disorder. Monitor nausea, insomnia, sexual dysfunction, hyponatremia, bleeding risk, serotonin syndrome risk, and discontinuation symptoms.
Low-dose paroxetine mesylate 7.5 mg	FDA-approved nonhormonal option for moderate to severe vasomotor symptoms	Not a treatment dose for major depressive disorder. Avoid strong CYP2D6 inhibition when tamoxifen interaction is a concern and alternatives are reasonable.
Gabapentin	Nocturnal vasomotor symptoms and sleep disruption	Monitor dizziness, somnolence, edema, gait instability, renal dosing, and fall risk.
Oxybutynin	Selected patients with vasomotor symptoms when other options are unsuitable	Monitor anticholinergic effects, including dry mouth, constipation, urinary retention, blurred vision, tachycardia, and cognitive burden.
Fezolinetant	FDA-approved nonhormonal option for moderate to severe vasomotor symptoms	Requires baseline and follow-up liver testing. Contraindicated with known cirrhosis, severe renal impairment or ESRD, and CYP1A2 inhibitors. Counsel patients about symptoms of liver injury.
Clonidine	Rarely preferred	No longer favored because benefit is limited and adverse effects can be problematic.

Management of Thyroid Dysfunction

Overt hypothyroidism is treated with levothyroxine. Dosing should be individualized by age, weight, pregnancy status, cardiac disease, severity of hypothyroidism, and adherence factors. Younger healthy adults may tolerate full replacement dosing. Older adults and patients with coronary disease usually require lower starting doses and slower titration.

TSH should be reassessed after initiation or dose changes, commonly in 4 to 8 weeks. For most adults, the goal is a TSH within the laboratory reference range. A narrow target such as 0.5 to 2.5 mIU/L should not be presented as universal. Pregnancy, thyroid cancer suppression, central hypothyroidism, advanced age, and residual thyroid function after hyperthyroidism treatment require different approaches.

Levothyroxine should not be used to treat nonspecific symptoms in biochemically euthyroid patients. If fatigue, weight gain, depression, or cognitive symptoms persist despite normal thyroid tests, the next step is reassessment for other causes rather than dose escalation that suppresses TSH.

Hyperthyroidism requires attention to etiology and severity. Beta-blockers can reduce adrenergic symptoms such as tremor, palpitations, and tachycardia while the diagnostic evaluation proceeds. Graves disease, toxic multinodular goiter, toxic adenoma, thyroiditis, iodine exposure, and medication-induced thyrotoxicosis require different management.

Methimazole is preferred for most nonpregnant patients with Graves disease who choose antithyroid drug therapy. Important exceptions include the first trimester of pregnancy, thyroid storm, and selected intolerance scenarios in which propylthiouracil may be used. Before antithyroid therapy, baseline CBC with differential and liver profile are appropriate. Patients should receive written instructions to stop the drug and contact the clinician immediately if fever, sore throat, jaundice, dark urine, pale stools, abdominal pain, severe fatigue, rash, or pharyngitis develops.

Urgent evaluation is required for suspected thyroid storm, severe thyrotoxicosis with arrhythmia, decompensated heart failure, altered mental status, severe hyperthermia, or marked weight loss. Endocrinology referral is appropriate for overt hyperthyroidism, unclear etiology, pregnancy, severe or recurrent disease, suspected central thyroid disease, nodules with thyrotoxicosis, or difficulty achieving stable control.

Table 5. Thyroid and Mood Medication Safety

Therapy	Role	Key cautions and monitoring
Levothyroxine	Standard therapy for overt hypothyroidism	Recheck TSH after dose changes, commonly in 4 to 8 weeks. Avoid overreplacement, which can increase atrial fibrillation, bone loss, tremor, anxiety, and insomnia.
Methimazole	Preferred antithyroid drug for most nonpregnant patients with Graves disease choosing medication therapy	Obtain baseline CBC with differential and liver profile. Counsel patients to stop the drug and call promptly for fever, sore throat, jaundice, dark urine, pale stools, abdominal pain, severe fatigue, or pharyngitis.
Propylthiouracil	Selected use in first trimester pregnancy, thyroid storm, or selected methimazole intolerance scenarios	Use selectively because of severe hepatotoxicity risk. Endocrinology involvement is usually appropriate.
SSRIs or SNRIs for depression or anxiety	First-line pharmacologic options when medication is indicated	Screen for bipolar disorder. Monitor activation, sleep effects, sexual dysfunction, GI effects, hyponatremia, bleeding risk, and suicidality early in treatment.
Benzodiazepines	Short-term crisis use in selected anxiety presentations	Avoid routine long-term use. Monitor sedation, falls, cognitive effects, dependence, respiratory risk with other sedatives, and alcohol interaction.
Psychotherapy, including CBT	Depression, anxiety, insomnia, and coping with symptom burden	Particularly useful when symptoms are mixed, chronic, stress-amplified, or medication avoidance is preferred.

Management of Mood Disorders During Midlife

Mood symptoms should be treated as clinically important even when perimenopause or thyroid disease is present. A medical contributor may explain part of the syndrome, but it does not rule out major depression, generalized anxiety disorder, panic disorder, bipolar disorder, trauma-related illness, or substance use disorder.

For major depressive disorder, evidence-based treatment includes psychotherapy, second-generation antidepressants, or both, guided by severity, patient preference, prior response, comorbidities, adverse-effect profile, drug interactions, and safety risk. Cognitive behavioral therapy is a reasonable first-line option for some patients with mild to moderate symptoms and may be combined with pharmacotherapy for more severe or persistent illness.

For anxiety disorders, cognitive behavioral therapy and SSRIs or SNRIs are common first-line approaches. Benzodiazepines may have a limited short-term role in selected cases, but they require caution because of sedation, falls, cognitive effects, dependence, respiratory risk with other sedatives, and alcohol interaction.

When vasomotor symptoms and mood symptoms coexist, medication selection can sometimes address both. Venlafaxine, desvenlafaxine, escitalopram, citalopram, and paroxetine have evidence for vasomotor symptom reduction, although psychiatric dosing, adverse-effect profiles, and drug interaction risks differ. Low-dose paroxetine mesylate for vasomotor symptoms should not be mistaken for adequate treatment of major depressive disorder.

A Stepwise Clinical Workflow

First, define the pattern. Determine whether symptoms are episodic, persistent, cyclic, abrupt, progressive, or temporally related to menses, medication changes, supplement use, alcohol, sleep disruption, or stress.

Second, assess reproductive stage and bleeding. Typical perimenopause can often be diagnosed clinically in patients aged 45 or older. Abnormal bleeding, postmenopausal bleeding, or bleeding with risk factors should be evaluated rather than attributed to perimenopause.

Third, test thyroid function when symptoms or findings justify case finding. TSH is the usual first test. Add free T4, T3, thyroid antibodies, or imaging selectively.

Fourth, screen mood and safety. Use PHQ-9 and GAD-7 to quantify symptoms and follow response. Confirm diagnoses clinically. Ask directly about suicidality and screen for bipolar disorder before antidepressant therapy.

Fifth, review medications and supplements. Ask specifically about biotin, thyroid hormone, amiodarone, lithium, stimulants, decongestants, antidepressants, anticholinergics, alcohol, cannabis, and high caffeine intake.

Sixth, treat confirmed conditions and reassess. When overt thyroid disease is present, treat it and reassess residual symptoms after biochemical improvement. When vasomotor symptoms dominate, discuss hormone therapy and nonhormonal options using individualized risk assessment. When depression or anxiety is present, initiate evidence-based mental health treatment rather than waiting indefinitely for endocrine or menopause management to resolve psychiatric symptoms.

Red Flags and Referral Triggers

Immediate or urgent evaluation is appropriate for suicidal ideation with intent or plan, psychosis, mania, inability to care for self, severe depression, suspected intimate partner violence, or substance withdrawal. Mood symptoms do not become low priority simply because menopause or thyroid disease is also plausible.

Urgent medical evaluation is appropriate for resting tachycardia with arrhythmia symptoms, syncope, chest pain, severe thyrotoxicosis, suspected thyroid storm, altered mental status, severe dehydration, or rapid unexplained weight loss.

Gynecologic evaluation is required for postmenopausal bleeding, heavy or prolonged bleeding, intermenstrual bleeding, postcoital bleeding, anemia related to bleeding, or abnormal bleeding in patients with risk factors for endometrial pathology.

Endocrinology referral is appropriate for overt hyperthyroidism, suspected Graves disease with orbitopathy, pregnancy-related thyroid disease, persistent unexplained thyroid test abnormalities, suspected central hypothyroidism, thyroid nodules with abnormal thyroid function, or difficulty stabilizing therapy.

Clinical Examples

A 47-year-old with skipped cycles, night sweats, episodic flushing, sleep fragmentation, normal heart rate, normal thyroid examination, and normal TSH most likely has perimenopause-associated vasomotor symptoms. FSH is unlikely to change management. Care should focus on symptom severity, contraception needs, bleeding evaluation when indicated, and shared decision-making about hormone therapy or nonhormonal options.

A 52-year-old with rapid-onset palpitations, tremor, heat intolerance, unintentional weight loss, resting tachycardia, low TSH, and elevated free T4 has thyrotoxicosis until proven otherwise. Treatment should include symptom control, evaluation of etiology, and timely endocrinology involvement. Anxiety symptoms should not be assumed to be primary panic disorder until the thyroid disorder is addressed.

A 45-year-old with persistent low mood, anhedonia, impaired function, guilt, insomnia, passive death wishes, normal TSH, and mild menstrual variability requires depression-focused management. Perimenopause may be relevant to timing and symptom burden, but it does not reduce the need for standard depression assessment and treatment.

A 50-year-old with fatigue, weight gain, constipation, dry skin, heavy menses, elevated TSH, and low free T4 has overt hypothyroidism. Levothyroxine is indicated. Mood symptoms should be reassessed after thyroid replacement is underway, but persistent depression should be treated directly.

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing.

Astellas Pharma US, Inc. (2026). VEOZAH (fezolinetant) tablets, for oral use: Prescribing information. Revised February 2026.

Clinical Guidelines Committee of the American College of Physicians. (2023). Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: A living clinical guideline from the American College of Physicians. Annals of Internal Medicine, 176(2), 239-253. doi: 10.7326/M22-2056

Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & STRAW+10 Collaborative Group. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10. Menopause, 19(4), 387-395. doi: 10.1097/gme.0b013e31824d8f40

Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., Sawka, A. M., & American Thyroid Association Task Force on Thyroid Hormone Replacement. (2014). Guidelines for the treatment of hypothyroidism. Thyroid, 24(12), 1670-1751. doi: 10.1089/thy.2014.0028

Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606-613. doi: 10.1046/j.1525-1497.2001.016009606.x

Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly, G., Bobo, W. V., Rubin, L. H., Koleva, H. K., Cohen, L. S., & Soares, C. N. (2018). Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations. Menopause, 25(10), 1069-1085. doi: 10.1097/GME.0000000000001174

National Institute for Health and Care Excellence. (2024). Menopause: Identification and management (NICE Guideline NG23). National Institute for Health and Care Excellence.

Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., & Walter, M. A. (2016). 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 26(10), 1343-1421. doi: 10.1089/thy.2016.0229

Santoro, N., Epperson, C. N., & Mathews, S. B. (2015). Menopausal symptoms and their management. Endocrinology and Metabolism Clinics of North America, 44(3), 497-515. doi: 10.1016/j.ecl.2015.05.001

Shufelt, C. L., Brown, V., Carpenter, J. S., Chism, L. A., Faubion, S. S., Joffe, H., Kling, J. M., Soares, C. N., & Thurston, R. C. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590. doi: 10.1097/GME.0000000000002200

Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092-1097. doi: 10.1001/archinte.166.10.1092

The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. doi: 10.1097/GME.0000000000002028

U.S. Preventive Services Task Force. (2015). Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 162(9), 641-650. doi: 10.7326/M15-0483